Saltar al contenido
Merck

Y0000475

Carboprost trometamol

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

(5Z,9α,11α,13E,15S)-9,11,15-Trihydroxy-15- methylprosta-5,13-dien-1-oic acid with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), Carboprost tromethamine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

40 MG
131,00 €

131,00 €


Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad

Solicitar un pedido a granel

Seleccione un Tamaño

Cambiar Vistas
40 MG
131,00 €

About This Item

Fórmula empírica (notación de Hill):
C25H47NO8
Número de CAS:
Peso molecular:
489.64
Número MDL:
Código UNSPSC:
41116107
NACRES:
NA.24

131,00 €


Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad

Solicitar un pedido a granel

grado

pharmaceutical primary standard

familia API

carboprost

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

−20°C

cadena SMILES

NC(CO)(CO)CO.O[C@H]1[C@H](C([C@H](C1)O)\C=C/[C@@](O)(CCCCC)C)C\C=C\CCCC(=O)O

InChI

1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5+,14-12-;/t16-,17?,18+,19-,21-;/m0./s1

Clave InChI

UMMADZJLZAPZAW-QFXCEMDRSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Carboprost trometamol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

L A Levine et al.
Cancer, 66(2), 242-245 (1990-07-15)
The treatment of cyclophosphamide-induced hemorrhagic cystitis has been difficult, with overall poor results using intensive and costly therapy. The authors evaluated the treatment of this problem in four patients with prostaglandin intravesical therapy. Each patient had failed to respond to
L A Levine et al.
The Journal of urology, 149(4), 719-723 (1993-04-01)
We review our experience with 18 consecutive patients who received intravesical carboprost tromethamine, an F2-alpha prostaglandin, for severe hemorrhagic cystitis following cyclophosphamide chemotherapy. Of the patients 16 were given cyclophosphamide for conditioning before bone marrow transplantation and 2 received the
Combined bladder and uterine rupture following prostaglandin-induced midtrimester abortion: an unreported event.
Umber Agarwal et al.
Acta obstetricia et gynecologica Scandinavica, 82(10), 974-975 (2003-09-06)
D M Kranc et al.
The Journal of urology, 148(4), 1326-1330 (1992-10-01)
Recently, prostaglandins have been shown to be effective agents for the treatment of cyclophosphamide-induced hemorrhagic cystitis. Among the prostaglandins studied is carboprost tromethamine, a PGF2a analog. To determine the effectiveness of carboprost tromethamine therapy on the urothelium, we induced hemorrhagic
Postpartum hemorrhage: new management options.
Gary A Dildy
Clinical obstetrics and gynecology, 45(2), 330-344 (2002-06-06)

Preguntas

Revisiones

Sin puntuación

Filtros activos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico